Help

Bloomberg

# Company In Depth Fundamentals - Profile

Ticker: GEHC US EQUITY

## GE HealthCare Technologies Inc (NASDAQ GS: GEHC, Currency: USD)

Sector: Salud  Industry: Equipo y servicios médicos  Sub-Industry: Equipo médico

| | |
|---|---|
| Website | www.gehealthcare.com |
| Number of Employees | 50,000 |
| Ticker: | GEHC US |

500 W Monroe Street 16th Floor Chicago, IL 60661 United States
Phone : 1-617-443-3400
Fax : --

75.06  +0.05 (0.07%)

GE HealthCare Technologies Inc. provides medical technology, pharmaceutical diagnostics, and digital solutions. The Company offers imaging, ultrasound, maternal, ventilator, and patient monitoring equipment, as well as performance management, cybersecurity, technical training, site planning, integrated asset optimization, and clinical network solutions.

FECHA: 18/12/2023

### Stock Quote & Chart (Currency: USD )

| | | | |
|---|---|---|---|
| Last (delayed quote) | 75.06 | Market Cap (MM) | 34,170.5 |
| Open | 75.00 | Shares Out. (MM) | 455.2 |
| Previous Close | 75.01 | Float % | 86.2% |
| Change | -0.91 | Shares sold short (MM) | 16,613,525.0 |
| Change % | -1.20 | Dividend Yield % | 0.1 |
| Day High/Day Low | 75.5 / 74.6 | Diluted EPS Excl. XO | |
| 52 Wk High/52 Wk low | 87.8 / 53.0 | P / Diluted EPS Before XO | |
| Volume (MM) | 1.92 | Beta | -- |
| Avg. Vol - 3 mo (MM) | 2.81 | | |




### Financial Information (Currency: USD, in mm)

| | | | |
|---|---|---|---|
| Revenue - LTM | 19,284.0 | Cash & ST Invst. | 1,539 |
| EBIT - LTM | 2,523.0 | Total Assets | 27,539.0 |
| EBITDA - LTM | 3,146.0 | Total Debt | 8,596.0 |
| Net Income - LTM | 1,719.0 | Total Liabilities | 17,947.0 |
| Total Enterprise Value | 42,185 | Total Equity | 9,592.0 |
| TEV/ Total Revenue | 2.0 x | Cash from Operations - LTM | 2,093.0 |
| TEV/ EBITDA | 12.4 x | Cash From Investing - LTM | -565.0 |
| | | Cash from Financing -LTM | 388.0 |

### Company Notes

2014 Q3
GAAP Net Income Includes: (in millions, pre-tax)
A loss of $71.000 from Other One Time Items
A loss of $15.000 from Restructuring
A gain of $15.000 from Sale of Investments

2014 Q2
GAAP Net Income Includes: (in millions, pre-tax)
A loss of $52.000 from Other One Time Items
A loss of $11.000 from Restructuring
A gain of $3.000 from Merger/Sale of investment
An after-tax loss of $115.000 from discontinued Operations

2014 Q1
GAAP Net Income Includes: (in millions, pre-tax)
A loss of $869 from Restructuring,123.0 from Other One Time Items,$201.0 from Merger Expenses & 6.000 from Sale of Investments. A loss of$146.0 from DiscountingOparetion.

2013 Q3
GAAP Net Income Includes: (in millions, pre-tax)
A loss of $257.000 from Other One Time Items
A loss of $18.000 from Restructuring
A loss of $13.000 from Merger/Acquisition Expense
A gain of $6.000 from Sale of Investments

2013 Q2
GAAP Net Income Includes: (in millions, pre-tax)

### Key Board Members

| | Name | Title | Organization |
|---|---|---|---|
| 1 | Risa J Lavizzo-Mourey | President Emerita | Robert Wood Johnson Foundation |
| 2 | | Lead Director | Ge Healthcare Technologies Inc |
| 3 | | Board Member | Better Therapeutics Inc |
| 4 | | Board Member | Merck & Co Inc |
| 5 | | Vice Chairman | Smithsonian Inst |
| 6 | | Board Member | Intel Corp |
| 7 | | Board Member | Lifemark Corp |
| 8 | | Board Member | Nellcor Puritan Bennett Inc |
| 9 | Henry Lawrence Culp "Larry" | Chief Executive Officer | Ge Aviation Llc |
| # | | Chairman/Ceo | General Electric Co |
| # | | Chief Executive Officer | Ge Aerospace Inc |
| # | | Chairman | Ge Healthcare Technologies Inc |
| # | | Trustee | Wake Forest University |
| # | | Board Member | Washington College |
| # | William Joseph Stromberg "Bill" | Board Member | Ge Healthcare Technologies Inc |
| # | | Chair | T Rowe Price Group Inc |
| # | | Trustee | Johns Hopkins University |
| # | Catherine A Lesjak "Cathie" | Board Member | Ge Healthcare Technologies Inc |
| # | | Board Member | Pros Holdings Inc |
| # | | Board Member | General Electric Co |
| # | | Board Member | Aruba Networks Inc |
| # | Peter J Arduini "Pete" | Senior Vp/Pres & Ceo:Healthcare | General Electric Co |
| # | | President/Ceo | Ge Healthcare Inc |
| # | | President/Chief Executive Officer | Ge Healthcare Technologies Inc |
| # | | Chair | Advanced Medical Tech Assn |
| # | | Board Member | Bristol-Myers Squibb Co |
| # | | Trustee | Susquehanna University |
| # | | Board Member | Medical Device Innovation Cons |
| # | | Board Member | Natl Italian American Fndn |

Bloomberg

# Company In Depth Fundamentals - Key Stats

| Ticker: | GEHC US EQUITY |
|---|---|
| Period Type | Annuals |

## GE HealthCare Technologies Inc

**Sector: Salud** **Industry: Equipo y servicios médicos** **Sub-Industry: Equipo médico**

Annuals

| FY | -6FY | -5FY | -4FY | -3FY | -2FY | -1FY | 0FY | -0FQ | 1FY | 2FY | 3FY |
|---|---|---|---|---|---|---|---|---|---|---|---|
| **Key Financials** | | | | | | | | | | | |
| | | | | **Actuals** | | | | **LTM** | **Estimates** | | |
| **For the Fiscal Period Ending** | -- | -- | -- | 31/12/2019 | 31/12/2020 | 31/12/2021 | 30/09/2023 | 30/09/2023 | 31/12/2023 | 31/12/2024 | 31/12/2025 |
| ***Currency*** | *USD* | *USD* | *USD* | *USD* | *USD* | *USD* | *USD* | *USD* | *USD* | *USD* | *USD* |
| **Total Revenue** | -- | -- | -- | 16,633.0 | 17,164.0 | 17,585.0 | 18,341.0 | 4,822.0 | 18,341.0 | 5,083.7 | 5,083.7 |
| *Growth Over Prior Year* | -- | -- | -- | -- | 3.2% | 2.5% | 4.3% | 7.2% | 3.0% | 3.0% | 3.0% |
| **Gross Profit** | -- | -- | -- | 6,548.0 | 6,767.0 | 7,174.0 | 7,179.0 | 7,698.0 | -- | -- | |
| *Margin %* | -- | -- | -- | 39.4% | 39.4% | 40.8% | 39.1% | 159.6% | -- | -- | -- |
| **EBITDA** | -- | -- | -- | 2,783.0 | 3,485.0 | 3,534.0 | 3,270.0 | 3,146.0 | 993.0 | 993.0 | 993.0 |
| *Margin %* | -- | -- | -- | 16.7% | 20.3% | 20.1% | 17.8% | 65.2% | 5.4% | 19.5% | 19.5% |
| **EBIT** | -- | -- | -- | 2,124.0 | 2,720.0 | 2,795.0 | 2,522.0 | 2,523.0 | 814.7 | 814.7 | 814.7 |
| *Margin %* | -- | -- | -- | 12.8% | 15.8% | 15.9% | 13.8% | 52.3% | 4.4% | 16.0% | 16.0% |
| **Earnings from Cont. Ops.** | -- | -- | -- | 1,681.0 | 2,058.0 | 2,275.0 | 1,949.0 | 1,769.0 | -- | -- | -- |
| *Margin %* | -- | -- | -- | 10.1% | 12.0% | 12.9% | 10.6% | 36.7% | -- | -- | -- |
| **Net Income** | -- | -- | -- | 1,524.0 | 13,846.0 | 2,247.0 | 1,916.0 | 1,719.0 | 489.6 | 489.6 | 489.6 |
| *Margin %* | -- | -- | -- | 9.2% | 80.7% | 12.8% | 10.4% | 35.6% | 2.7% | 9.6% | 9.6% |
| **Diluted EPS Excl. Extra Items** | -- | -- | -- | -- | -- | 4.9 | 4.1 | 3.3 | 1.1 | 1.1 | 1.1 |
| *Growth Over Prior Year* | -- | -- | -- | -- | -- | -- | *(15.5%)* | *(20.3%)* | *(18.1%)* | *(18.1%)* | *(18.1%)* |

| Current Capitalization (Millions ) | |
|---|---|
| **Currency** | **USD** |
| Share Price (USD) | 75.06 |
| Shares Out. | 455.24 |
| **Market Capitalization (USD)** | **34,170.54** |
| - Cash & Short Term Investments | 2,418.00 |
| + Total Debt | 10,260.00 |
| + Pref. Equity | 0.00 |
| + Total Minority Interest | 172.00 |
| **= Total Enterprise Value (USD)** | **42,184.54** |
| Book Value of Common Equity | 7,131.00 |
| + Pref. Equity | 0.00 |
| + Total Minority Interest | 172.00 |
| + Total Debt | 10,260.00 |
| **= Total Capital** | **17,563.00** |




| Valuation Multiples based on Current Capitalization | | | | | |
|---|---|---|---|---|---|
| | **Actual** | **LTM** | **Estimates** | | |
| **For the Fiscal Period Ending** | **30/09/2023** | **30/09/2023** | **30/09/2023** | **30/09/2023** | **30/09/2023** |
| TEV/Total Revenue | 1.8x | 2.0x | 8.2x | 8.2x | 8.2x |
| TEV/EBITDA | 10.3x | 12.4x | 11.2x | 11.2x | 11.2x |
| TEV/EBIT | 13.3x | 15.5x | 13.5x | 13.5x | 13.5x |
| P/Diluted EPS Before Extra | 14.1x | 20.3x | | | |
| P/BV | 2.8x | 4.3x | -- | -- | -- |
| Price/Tang BV | -- | -- | | | |

| Valuation Multiples for Chart | | | | |
|---|---|---|---|---|
| **For the Fiscal Period Ending** | **TTM** | **FY1** | **NTM** | **FY2** |
| PE Ratio | 20.3x | 18.6x | 18.6x | 18.6x |
| TEV / EBITDA | 12.4x | 11.2x | 11.2x | 11.2x |
| Price / CF | 16.3x | 13.7x | 13.7x | 13.7x |
| Price / Book | 4.8x | 0.0x | 0.0x | 0.0x |
| Dividend Yield | 0.1x | 0.5x | 0.5x | 0.5x |

**PE Ratio**



| Ticker: | GEHC US EQUITY | GEHC US EQUITY | Ascend | Currency | Reporting | Change | USD |
|---|---|---|---|---|---|---|---|
| Period Type | Annuals | Consolidated | Yes | Accounting | Mixed | | |

# GE HealthCare Technologies Inc

**Sector: Salud** **Industry: Equipo y servicios médicos** **Sub-Industry: Equipo médico**

| Y | -10FY | -9FY | -8FY | -7FY | -6FY | -5FY | -4FY | -3FY | -2FY | -1FY | -0FY |
|---|---|---|---|---|---|---|---|---|---|---|---|
| **Income Statement** | | | | | | | | | | | |
| **Income Sheet as of:** | - | - | - | - | - | - | -- | 31/12/2019 | 31/12/2020 | 31/12/2021 | 31/12/2022 |
| ***Currency*** | *USD* | *USD* | *USD* | *USD* | *USD* | *USD* | *USD* | *USD* | *USD* | *USD* | *USD* |
| Revenue | - | - | - | - | - | - | - | 16,633.00 | 17,164.00 | 17,585.00 | 18,341.00 |
| Other Revenue | - | - | - | - | - | - | - | - | - | - | - |
| **Total Revenue** | **-** | **-** | **-** | **-** | **-** | **-** | **-** | **16,633.00** | **17,164.00** | **17,585.00** | **18,341.00** |
| Cost Of Goods Sold | - | - | - | - | - | - | - | 10,085.00 | 10,397.00 | 10,411.00 | 11,162.00 |
| **Gross Profit** | **-** | **-** | **-** | **-** | **-** | **-** | **-** | **6,548.00** | **6,767.00** | **7,174.00** | **7,179.00** |
| Selling General & Admin Exp. | - | - | - | - | - | - | - | 3,591.00 | 3,237.00 | 3,563.00 | 3,631.00 |
| R & D Exp. | - | - | - | - | - | - | - | 833.00 | 810.00 | 816.00 | 1,026.00 |
| Depreciation & Amort. | - | - | - | - | - | - | - | - | - | - | - |
| Other Operating Expense/(Income) | - | - | - | - | - | - | - | - | - | - | - |
| **Operating Expense., Total** | **-** | **-** | **-** | **-** | **-** | **-** | **-** | **4,424.00** | **4,047.00** | **4,379.00** | **4,657.00** |
| **Operating Income** | **-** | **-** | **-** | **-** | **-** | **-** | **-** | **2,124.00** | **2,720.00** | **2,795.00** | **2,522.00** |
| Interest Expense | - | - | - | - | - | - | - | 88.00 | 66.00 | 40.00 | 77.00 |
| Interest Income | - | - | - | - | - | - | - | - | - | - | - |
| **Net Interest Exp.** | **-** | **-** | **-** | **-** | **-** | **-** | **-** | **88.00** | **66.00** | **40.00** | **77.00** |
| Currency Exchange Gains (Loss) | - | - | - | - | - | - | - | - | - | - | - |
| Other Non-Operating Inc. (Exp.) | - | - | - | - | - | - | - | (55.00) | (56.00) | (120.00) | (67.00) |
| **EBT Excl. Unusual Items** | **-** | **-** | **-** | **-** | **-** | **-** | **-** | **2,091.00** | **2,710.00** | **2,875.00** | **2,512.00** |
| Impairment of Goodwill | - | - | - | - | - | - | - | - | - | - | - |
| Gain (Loss) On Sale Of Assets | - | - | - | - | - | - | - | - | - | - | - |
| Asset Writedown | - | - | - | - | - | - | - | - | - | - | - |
| Legal Settlements | - | - | - | - | - | - | - | - | - | - | - |
| Other Unusual Items | - | - | - | - | - | - | - | - | - | - | - |
| **EBT Incl. Unusual Items** | **-** | **-** | **-** | **-** | **-** | **-** | **-** | **2,091.00** | **2,710.00** | **2,875.00** | **2,512.00** |
| Income Tax Expense | - | - | - | - | - | - | - | 410.00 | 652.00 | 600.00 | 563.00 |
| **Earnings from Cont. Ops.** | **-** | **-** | **-** | **-** | **-** | **-** | **-** | **1,681.00** | **2,058.00** | **2,275.00** | **1,949.00** |
| Extraord. Item & Account. Change | - | - | - | - | - | - | - | 128.00 | (11,839.00) | (18.00) | (18.00) |
| Minority Int. in Earnings | - | - | - | - | - | - | - | 29.00 | 51.00 | 46.00 | 51.00 |
| **Net Income** | **-** | **-** | **-** | **-** | **-** | **-** | **-** | **1,524.00** | **13,846.00** | **2,247.00** | **1,916.00** |
| Pref. Dividends | - | - | - | - | - | - | - | - | - | - | - |
| Other Adj | - | - | - | - | - | - | - | - | - | - | - |
| **NI to Common Incl Extra Items** | **-** | **-** | **-** | **-** | **-** | **-** | **-** | **1,524.00** | **13,846.00** | **2,247.00** | **1,916.00** |
| Abnormal Losses (Gains) | - | - | - | - | - | - | - | 161.00 | 112.00 | 152.00 | 177.00 |
| Tax Effect on Abnormal Items | - | - | - | - | - | - | - | (33.81) | (23.52) | (31.92) | (37.17) |
| **NI to Common Excl. Extra Items** | **-** | **-** | **-** | **-** | **-** | **-** | **-** | **1,651.19** | **13,934.48** | **2,367.08** | **2,055.83** |
| **Per Share Items** | | | | | | | | | | | |
| Basic EPS | - | - | - | - | - | - | - | - | - | 4.94 | 4.18 |
| Basic EPS Excl. Extra Items | - | - | - | - | - | - | - | - | - | 4.90 | 4.17 |
| Weighted Avg. Basic Shares Out. | - | - | - | - | - | - | - | - | - | 454.71 | 454.71 |
| Diluted EPS | - | - | - | - | - | - | - | - | - | 4.94 | 4.18 |
| Diluted EPS Excl. Extra Items | - | - | - | - | - | - | - | - | - | 4.90 | 4.14 |
| Weighted Avg. Diluted Shares Out. | - | - | - | - | - | - | - | - | - | 454.71 | 454.71 |
| Normalized Basic EPS | - | - | - | - | - | - | - | - | - | - | 4.63 |
| Normalized Diluted EPS | - | - | - | - | - | - | - | - | - | 5.17 | 4.45 |
| Dividends per Share | | | | | | | | | | | |
| Payout Ratio % | - | - | - | - | - | - | - | - | - | - | - |
| **Supplemental Items** | | | | | | | | | | | |
| EBITA | - | - | - | - | - | - | - | 2,558.00 | 3,263.00 | 3,309.00 | 3,042.00 |
| EBIT | - | - | - | - | - | - | - | 2,124.00 | 2,720.00 | 2,795.00 | 2,522.00 |
| As Reported Total Revenue* | - | - | - | - | - | - | - | 16,633.00 | 17,164.00 | 17,585.00 | 18,341.00 |
| Effective Tax Rate % | - | - | - | - | - | - | - | 19.61 | 24.06 | 20.87 | 22.41 |
| Normalized Net Income | - | - | - | - | - | - | - | 1,779.19 | 2,095.48 | 2,349.08 | 2,037.83 |
| Interest Capitalized | - | - | - | - | - | - | - | - | - | - | - |
| **Supplemental Operating Expense Items** | | | | | | | | | | | |
| Net Rental Exp. | - | - | - | - | - | - | - | - | - | - | - |
| Stock-Based Comp., Unallocated | - | - | - | - | - | - | - | - | - | - | - |
| **Stock-Based Comp., Total** | **-** | **-** | **-** | **-** | **-** | **-** | **-** | **-** | **-** | **-** | **-** |

| Ticker: | GEHC US EQUITY | GEHC US EQUITY | Ascend | Currency | Reporting | Change | USD |
|---|---|---|---|---|---|---|---|
| Period Type | Annuals | Consolidated | Yes | Accounting | Mixed | | |

# GE HealthCare Technologies Inc

Sector: Salud  Industry: Equipo y servicios médicos  Sub-Industry: Equipo médico

| Y | -10FY | -9FY | -8FY | -7FY | -6FY | -5FY | -4FY | -3FY | -2FY | -1FY | -0FY |
|---|---|---|---|---|---|---|---|---|---|---|---|
| **Balance Sheet** | | | | | | | | | | | |
| **Balance Sheet as of:** | -- | -- | -- | -- | -- | -- | -- | 31/12/2019 | 31/12/2020 | 31/12/2021 | 31/12/2022 |
| **Currency** | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| **ASSETS** | | | | | | | | | | | |
| Cash And Equivalents | - | - | - | - | - | - | - | - | 1,007.00 | 556.00 | 1,445.00 |
| Short Term Investments | - | - | - | - | - | - | - | - | 98.00 | 88.00 | 94.00 |
| **Total Cash & ST Investments** | - | - | - | - | - | - | - | - | **1,105.00** | **644.00** | **1,539.00** |
| Accounts & Notes Receivable | - | - | - | - | - | - | - | - | 2,002.00 | 3,326.00 | 3,392.00 |
| **Total Receivables** | - | - | - | - | - | - | - | - | **2,002.00** | **3,326.00** | **3,392.00** |
| Inventories | - | - | - | - | - | - | - | - | 1,594.00 | 1,946.00 | 2,155.00 |
| Prepaid Exp. | - | - | - | - | - | - | - | - | - | - | - |
| Restricted Cash | - | - | - | - | - | - | - | - | - | - | - |
| Other Current Assets | - | - | - | - | - | - | - | - | 1,320.00 | 1,183.00 | 1,329.00 |
| **Total Current Assets** | - | - | - | - | - | - | - | - | **6,021.00** | **7,099.00** | **8,415.00** |
| **Net Property, Plant & Equipment** | - | - | - | - | - | - | - | - | **2,202.00** | **2,235.00** | **2,314.00** |
| Long-term Investments | - | - | - | - | - | - | - | - | - | - | - |
| Deferred Charges, LT | - | - | - | - | - | - | - | - | 1,489.00 | 1,287.00 | 1,550.00 |
| Other Long-Term Assets | - | - | - | - | - | - | - | - | 14,641.00 | 15,786.00 | 15,357.00 |
| **Total Assets** | - | - | - | - | - | - | - | - | **24,353.00** | **26,407.00** | **27,636.00** |
| **LIABILITIES** | | | | | | | | | | | |
| Accrued Exp. | - | - | - | - | - | - | - | - | - | - | - |
| Short-term Borrowings | - | - | - | - | - | - | - | - | 132.00 | 110.00 | 119.00 |
| Accounts Payable | - | - | - | - | - | - | - | - | 2,162.00 | 2,540.00 | 2,944.00 |
| Curr. Income Taxes Payable | - | - | - | - | - | - | - | - | - | - | - |
| Other Current Liabilities | - | - | - | - | - | - | - | - | 4,230.00 | 4,111.00 | 4,128.00 |
| **Total Current Liabilities** | - | - | - | - | - | - | - | - | **6,524.00** | **6,761.00** | **7,191.00** |
| Long-Term Debt | - | - | - | - | - | - | - | - | 314.00 | 293.00 | 8,477.00 |
| Unearned Revenue, Non-Current | - | - | - | - | - | - | - | - | - | - | - |
| Other Non-Current Liabilities | - | - | - | - | - | - | - | - | 2,416.00 | 2,358.00 | 2,279.00 |
| **Total Liabilities** | - | - | - | - | - | - | - | - | **9,254.00** | **9,412.00** | **17,947.00** |
| Pref. Stock, Non-Redeem. | - | - | - | - | - | - | - | - | - | - | - |
| **Total Pref. Equity** | - | - | - | - | - | - | - | - | - | - | - |
| Minority Interest | - | - | - | - | - | - | - | - | 247.00 | 241.00 | 235.00 |
| Additional Paid In Capital | - | - | - | - | - | - | - | - | - | - | - |
| Retained Earnings | - | - | - | - | - | - | - | - | - | - | - |
| Treasury Stock | - | - | - | - | - | - | - | - | - | - | - |
| Comprehensive Inc. and Other | - | - | - | - | - | - | - | - | 14,727.00 | 16,655.00 | 9,357.00 |
| **Total Common Equity** | - | - | - | - | - | - | - | - | **14,974.00** | **16,896.00** | **9,592.00** |
| **Total Equity** | - | - | - | - | - | - | - | - | **14,974.00** | **16,896.00** | **9,592.00** |
| **Total Liabilities And Equity** | - | - | - | - | - | - | - | - | **24,228.00** | **26,308.00** | **27,539.00** |
| **Supplemental Items** | | | | | | | | | | | |
| Total Shares Out. on Filing Date | - | - | - | - | - | - | - | - | - | 454.71 | 454.71 |
| Total Shares Out. on Balance Sheet Date | - | - | - | - | - | - | - | - | - | 454.71 | 454.71 |
| Book Value/Share | - | - | - | - | - | - | - | - | - | 36.63 | 20.58 |
| Tangible Book Value | - | - | - | - | - | - | - | - | - | 1,916.00 | (4,976.00) |
| Tangible Book Value/Share | - | - | - | - | - | - | - | - | - | 4.21 | (10.94) |
| Total Debt | - | - | - | - | - | - | - | - | 446.00 | 403.00 | 8,596.00 |
| Net Debt | - | - | - | - | - | - | - | - | (659.00) | (241.00) | 7,057.00 |
| Total Minority Interest | - | - | - | - | - | - | - | - | 247.00 | 241.00 | 235.00 |
| Inventory Method | First-in-first-out) | First-in-first-out) | First-in-first-out) | First-in-first-out) | First-in-first-out) | First-in-first-out) | First-in-first-out) | First-in-first-out) | First-in-first-out) | First-in-first-out) | First-in-first-out) |
| Raw Materials in Inventory | - | - | - | - | - | - | - | - | - | - | - |
| Work in Progress Inventory | - | - | - | - | - | - | - | - | - | - | - |
| Finished Goods Inventory | - | - | - | - | - | - | - | - | - | - | - |
| Other Inventory Accounts | - | - | - | - | - | - | - | - | - | - | - |
| Accum. Allowance for Doubtful Accts | - | - | - | - | - | - | - | - | 93.00 | 107.00 | 91.00 |
| Full Time Employees | - | - | - | - | - | - | - | - | - | - | 50,000.00 |

Bloomberg

# Company In Depth Fundamentals - Cash Flow Statement

| Ticker: | GEHC US EQUITY | Sort | Ascend | Currency Selection | Reporting | Change | USD |
|---|---|---|---|---|---|---|---|
| Period Type | Annuals | Consolidated | Yes | Accounting Standard | Mixed | | |

## GE HealthCare Technologies Inc

**Sector: Salud** **Industry: Equipo y servicios médicos** **Sub-Industry: Equipo médico**

| Y | -10FY | -9FY | -8FY | -7FY | -6FY | -5FY | -4FY | -3FY | -2FY | -1FY | -0FY |
|---|---|---|---|---|---|---|---|---|---|---|---|
| **Cash Flow** | | | | | | | | | | | |
| **For the Fiscal Period Ending** | -- | -- | -- | -- | -- | -- | -- | 31/12/2019 | 31/12/2020 | 31/12/2021 | 31/12/2022 |
| ***Currency*** | *USD* | *USD* | *USD* | *USD* | *USD* | *USD* | *USD* | *USD* | *USD* | *USD* | *USD* |
| **Net Income** | - | - | - | - | - | - | - | **1,524.00** | **13,846.00** | **2,247.00** | **1,916.00** |
| **Depreciation & Amort., Total** | - | - | - | - | - | - | - | **659.00** | **630.00** | **625.00** | **633.00** |
| Other Non-Cash Adj | - | - | - | - | - | - | - | 130.00 | (11,879.00) | 241.00 | (200.00) |
| Changes in Non-Cash Capital | - | - | - | - | - | - | - | (475.00) | 21.00 | (1,506.00) | (236.00) |
| **Cash from Ops.** | - | - | - | - | - | - | - | **1,838.00** | **2,618.00** | **1,607.00** | **2,113.00** |
| | | | | | | | | | | | |
| Capital Expenditure | - | - | - | - | - | - | - | (263.00) | (237.00) | (242.00) | (310.00) |
| Sale of Property, Plant, and Equipment | - | - | - | - | - | - | - | 52.00 | 16.00 | 15.00 | 4.00 |
| Cash Acquisitions | - | - | - | - | - | - | - | - | - | - | - |
| Proceeds from Investment | - | - | - | - | - | - | - | - | - | - | - |
| Divestitures | - | - | - | - | - | - | - | - | - | - | - |
| Invest. in Marketable & Equity Securt. | - | - | - | - | - | - | - | - | - | - | - |
| Other Investing Activities | - | - | - | - | - | - | - | (102.00) | (102.00) | (1,534.00) | (92.00) |
| **Cash from Investing** | - | - | - | - | - | - | - | **(313.00)** | **(323.00)** | **(1,761.00)** | **(398.00)** |
| | | | | | | | | | | | |
| Net Short Term Debt Issued/Repaid | - | - | - | - | - | - | - | - | (10.00) | (7.00) | 9.00 |
| Long-Term Debt Issued | - | - | - | - | - | - | - | 4.00 | 4.00 | 5.00 | 8,198.00 |
| Long-Term Debt Repaid | - | - | - | - | - | - | - | (63.00) | (10.00) | (10.00) | (3.00) |
| **Total Debt Issued/Repaid** | - | - | - | - | - | - | - | **(59.00)** | **(16.00)** | **(12.00)** | **8,204.00** |
| | | | | | | | | | | | |
| Pref. Dividends Paid | - | - | - | - | - | - | - | - | - | - | - |
| **Total Dividends Paid** | - | - | - | - | - | - | - | - | - | - | - |
| | | | | | | | | | | | |
| Increase in CapItal Stocks | - | - | - | - | - | - | - | - | - | - | - |
| Decrease in Capital Stocks | - | - | - | - | - | - | - | (1,334.00) | (2,098.00) | (238.00) | (8,934.00) |
| Special Dividend Paid | - | - | - | - | - | - | - | - | - | - | - |
| Incr(Decr) in Deposits | - | - | - | - | - | - | - | - | - | - | - |
| Incr(Decr) Insurance Reserves | - | - | - | - | - | - | - | - | - | - | - |
| Other Financing Activities | - | - | - | - | - | - | - | (97.00) | (38.00) | (47.00) | (95.00) |
| **Cash from Financing** | - | - | - | - | - | - | - | **(1,490.00)** | **(2,152.00)** | **(297.00)** | **(825.00)** |
| | | | | | | | | | | | |
| **Net Change in Cash** | - | - | - | - | - | - | - | **35.00** | **143.00** | **(451.00)** | **890.00** |
| | | | | | | | | | | | |
| **Supplemental Items** | | | | | | | | | | | |
| Cash Interest Paid | - | - | - | - | - | - | - | 73.00 | 46.00 | 21.00 | - |
| Cash Taxes Paid | - | - | - | - | - | - | - | 503.00 | 809.00 | 615.00 | 851.00 |
| Free Cash Flow | - | - | - | - | - | - | - | 1,575.00 | 2,381.00 | 1,365.00 | 1,803.00 |
| Change in Net Working Capital | - | - | - | - | - | - | - | - | - | - | - |

Bloomberg

# Company In Depth Fundamentals - Multiples

| Ticker: | GEHC US EQUITY | Sort | Ascend | | |
|---|---|---|---|---|---|
| Period Type | Annuals | Consolidated | Yes | Accounting | Mixed |

## GE HealthCare Technologies Inc

Sector: Salud  Industry: Equipo y servicios médicos  Sub-Industry: Equipo médico

| Y | | -10FY | -9FY | -8FY | -7FY | -6FY | -5FY | -4FY | -3FY | -2FY | -1FY | -0FY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| **Multiples** | | | | | | | | | | | | |
| | | -- | -- | -- | -- | -- | -- | -- | 31/12/2019 | 31/12/2020 | 31/12/2021 | 31/12/2022 |
| **TEV / LTM Total Revenue** | **Close** | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | **1.8x** |
| | Average | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| | High | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| | Low | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| **TEV / LTM EBITDA** | **Close** | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | **10.3x** |
| | Average | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| | High | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| | Low | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| **TEV / LTM EBIT** | **Close** | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | **13.3x** |
| | Average | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| | High | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| | Low | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| **Price / LTM EPS** | **Close** | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | **13.1x** |
| | Average | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 11.3x |
| | High | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 13.1x |
| | Low | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 10.9x |
| **Price / Book Value** | **Close** | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | **2.8x** |
| | Average | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 1.7x |
| | High | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 2.8x |
| | Low | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 1.5x |
| **Price / Tangible Book Value** | **Close** | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | **--** |
| | Average | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 13.7x |
| | High | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 14.2x |
| | Low | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 13.4x |
| **Price / Cash Flow** | **Close** | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | **12.6x** |
| | Average | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 15.9x |
| | High | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 17.0x |
| | Low | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 12.6x |
| **TEV / LTM FCF** | **Close** | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | **14.7x** |
| | Average | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 18.8x |
| | High | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 20.0x |
| | Low | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 14.7x |
| **Dividend Yield** | **Close** | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | **0.0** |
| | Average | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.0 |
| | High | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.0 |
| | Low | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.0 |

| Ticker: | GEHC US EQUITY | GEHC US EQUITY | Ascend | | | |
|---|---|---|---|---|---|---|
| Period Type | Quarters | Consolidated | Yes | Accounting | Mixed | |

# GE HealthCare Technologies Inc

**Sector: Salud** **Industry: Equipo y servicios médicos** **Sub-Industry: Equipo médico**

| Y | -10FQ | -9FQ | -8FQ | -7FQ | -6FQ | -5FQ | -4FQ | -3FQ | -2FQ | -1FQ | -0FQ |
|---|---|---|---|---|---|---|---|---|---|---|---|
| **Ratios** | | | | | | | | | | | |
| **For the Fiscal Period Ending** | **31/03/2021** | **30/06/2021** | **23/09/2021** | **31/12/2021** | **31/03/2022** | **30/06/2022** | **30/09/2022** | **31/12/2022** | **31/03/2023** | **30/06/2023** | **30/09/2023** |
| **Profitability** | | | | | | | | | | | |
| Return on Assets | -- | -- | -- | -- | -- | -- | -- | 7.1% | -- | 6.2% | 5.9% |
| Return on Capital | -- | -- | -- | -- | -- | -- | -- | 11.4% | -- | 12.3% | 12.2% |
| Return on Equity | -- | -- | -- | -- | -- | -- | -- | 14.7% | -- | 15.2% | 14.3% |
| **Margin Analysis** | | | | | | | | | | | |
| Gross Margin | 40.4% | 41.2% | 41.0% | 40.6% | 38.6% | 40.1% | 38.7% | 39.1% | 40.2% | 40.3% | 40.1% |
| SG&A Margin | -- | -- | -- | -- | -- | -- | -- | -- | 21.1% | 20.6% | 19.5% |
| EBITDA Margin | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 16.3% |
| EBIT Margin | -- | -- | -- | 15.9% | 15.0% | 14.2% | 13.7% | 13.8% | 13.8% | 13.2% | 13.1% |
| Earnings from Cont. Ops Margin | 15.6% | 17.0% | 15.2% | 15.8% | 11.7% | 14.1% | 13.2% | 15.7% | 11.9% | 11.8% | 12.8% |
| Net Income Margin | 11.9% | 14.9% | 11.9% | 12.3% | 8.9% | 10.8% | 10.6% | 11.2% | 7.9% | 8.7% | 7.8% |
| Normalized Net Income Margin | 11.8% | 14.8% | 11.7% | 12.3% | 8.9% | 10.5% | 10.6% | 11.1% | 9.0% | 10.2% | 8.5% |
| Free Cash Flow Margin | -- | -- | -- | -1.8% | -- | -- | -- | 19.5% | 6.9% | -2.8% | 11.8% |
| **Asset Turnover** | | | | | | | | | | | |
| Total Asset Turnover | -- | -- | -- | -- | -- | -- | -- | 0.7x | -- | 0.6x | 0.7x |
| Fixed Asset Turnover | -- | -- | -- | -- | -- | -- | -- | 8.1x | -- | 8.4x | 8.7x |
| Accounts Receivable Turnover | -- | -- | -- | -- | -- | -- | -- | 5.5x | -- | 5.7x | 6.0x |
| Inventory Turnover | -- | -- | -- | -- | -- | -- | -- | 5.4x | -- | 5.1x | 5.4x |
| **Short Term Liquidity** | | | | | | | | | | | |
| Current Ratio | -- | -- | -- | 1.0x | -- | 1.1x | 1.1x | 1.2x | 1.2x | 1.2x | 1.3x |
| Quick Ratio | -- | -- | -- | 0.6x | -- | 0.6x | 0.5x | 0.7x | 0.7x | 0.7x | 0.8x |
| Cash from Ops. To Curr Liab | -- | -- | -- | 0.1x | -- | 0.1x | 0.1x | 0.7x | 0.5x | 0.5x | 0.5x |
| Ave. Days Sales Out | -- | -- | -- | -- | -- | -- | -- | 66.8x | -- | 63.5x | 61.0x |
| Ave. Days Inventory Out | -- | -- | -- | -- | -- | -- | -- | 67.1x | -- | 71.4x | 68.7x |
| Ave. Days Payable Out | -- | -- | -- | -- | -- | -- | -- | 88.0x | -- | 87.6x | 86.6x |
| Ave. Cash Conversion Cycle | -- | -- | -- | -- | -- | -- | -- | 45.9x | -- | 47.3x | 43.6x |
| **Long Term Solvency** | | | | | | | | | | | |
| Total Debt/Equity | -- | -- | -- | 7.4% | -- | 0.7% | 0.3% | 89.6% | 148.5% | 139.8% | 140.5% |
| Total Debt/Capital | -- | -- | -- | 7.3% | -- | 0.7% | 0.3% | 47.3% | 59.8% | 58.3% | 58.4% |
| LT Debt/Equity | -- | -- | -- | 1.8% | -- | 0.7% | 0.3% | 90.6% | 153.0% | 144.1% | 143.8% |
| LT Debt/Capital | -- | -- | -- | 1.7% | -- | 0.7% | 0.3% | 46.6% | 59.7% | 58.3% | 58.4% |
| Total Liabilities/Total Assets | -- | -- | -- | 10.1% | -- | 9.4% | 9.0% | 39.1% | 53.6% | 53.0% | 54.1% |
| EBIT / Interest Exp | 44.33x | 83.33x | 65.30x | 131.17x | 177.75x | 57.58x | 307.50x | 13.17x | 4.11x | 4.16x | 4.47x |
| EBITDA / Interest Exp | -- | -- | -- | 146.83x | -- | -- | -- | 15.83x | 5.76x | 5.30x | 5.58x |
| (EBITDA-CAPEX) / Interest Exp | -- | -- | -- | 134.67x | -- | -- | -- | 14.53x | 4.31x | 4.79x | 5.00x |
| Total Debt/EBITDA | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 3.36x |
| Net Debt/EBITDA | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 2.89x |
| Altman Z Score | -- | -- | -- | -- | -- | -- | -- | 4.0 | 3.46 | 3.55 | 3.46 |
| **Growth Over Prior Year** | | | | | | | | | | | |
| Total Revenue | -- | -- | -- | -- | 1.6% | 1.6% | 6.3% | 7.6% | 8.6% | 7.4% | 5.4% |
| Gross Profit | -- | -- | -- | -- | (2.9%) | (1.7%) | 0.3% | 3.8% | 13.7% | 8.0% | 9.1% |
| EBITDA | -- | -- | -- | -- | -- | -- | -- | 6.0% | -- | -- | -- |
| EBITA | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| EBIT | -- | -- | -- | -- | (33.5%) | (15.0%) | (7.4%) | 6.9% | 9.8% | (9.7%) | 7.0% |
| Earnings from Cont. Ops | -- | -- | -- | -- | (37.4%) | (37.7%) | (4.6%) | (1.6%) | (4.0%) | (10.9%) | (31.7%) |
| Net Income | -- | -- | -- | -- | (34.9%) | (36.4%) | (5.9%) | (1.8%) | (3.6%) | (11.8%) | (33.0%) |
| Normalized Net Income | -- | -- | -- | -- | (33.7%) | (37.8%) | (3.4%) | (2.8%) | 9.9% | 4.7% | (16.0%) |
| Diluted EPS before Extra | -- | -- | -- | -- | (33.7%) | (37.8%) | (3.4%) | (3.6%) | (51.7%) | (13.5%) | (37.7%) |
| Accounts Receivable | -- | -- | -- | -- | -- | -- | -- | 7.0% | -- | 3.6% | 9.7% |
| Inventory | -- | -- | -- | -- | -- | -- | -- | 10.7% | -- | 1.7% | 13.3% |
| Net PP&E | -- | -- | -- | -- | -- | -- | -- | 3.5% | -- | 0.1% | 13.3% |
| Total Assets | -- | -- | -- | -- | -- | -- | -- | 4.7% | -- | 37.1% | 34.7% |
| Tangible Book Value | -- | -- | -- | -- | -- | -- | -- | (359.7%) | -- | (388.6%) | (385.0%) |
| Common Equity | -- | -- | -- | -- | -- | -- | -- | (43.8%) | -- | (58.3%) | (57.7%) |
| Cash from Ops. | -- | -- | -- | -- | -- | -- | -- | (9.577.7%) | -- | -- | -- |
| Capital Expenditures | -- | -- | -- | -- | -- | -- | -- | 5.5% | -- | -- | -- |
| Levered Free Cash Flow | -- | -- | -- | -- | -- | -- | -- | (1.348.8%) | -- | -- | -- |
| Unlevered Free Cash Flow | -- | -- | -- | -- | -- | -- | -- | (1.348.8%) | -- | -- | -- |
| Dividend per Share | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| **CAGR Over Two Years** | | | | | | | | | | | |
| Total Revenue | -- | -- | -- | -- | -- | -- | -- | -- | 4.9% | 4.5% | 5.8% |
| Gross Profit | -- | -- | -- | -- | -- | -- | -- | -- | 4.6% | 3.3% | 4.6% |
| EBITDA | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| EBITA | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| EBIT | -- | -- | -- | -- | -- | -- | -- | -- | (8.3%) | (13.8%) | (3.8%) |
| Earnings from Cont. Ops | -- | -- | -- | -- | -- | -- | -- | -- | (13.7%) | (14.5%) | (13.6%) |
| Net Income | -- | -- | -- | -- | -- | -- | -- | -- | (14.6%) | (30.4%) | (14.6%) |
| Normalized Net Income | -- | -- | -- | -- | -- | -- | -- | -- | (8.4%) | (13.3%) | (4.9%) |
| Diluted EPS before Extra | -- | -- | -- | -- | -- | -- | -- | -- | (34.3%) | (30.5%) | (13.3%) |
| Accounts Receivable | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Inventory | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Net PP&E | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Total Assets | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Tangible Book Value | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Common Equity | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Cash from Ops. | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Capital Expenditures | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Levered Free Cash Flow | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Unlevered Free Cash Flow | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Dividend per Share | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| **CAGR Over Three Years** | | | | | | | | | | | |
| Total Revenue | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| EBITDA | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| EBITA | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| EBIT | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Earnings from Cont. Ops | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Net Income | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Normalized Net Income | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Diluted EPS before Extra | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Accounts Receivable | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Inventory | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Net PP&E | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Total Assets | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Tangible Book Value | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Common Equity | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Cash from Ops. | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Capital Expenditures | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Levered Free Cash Flow | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Unlevered Free Cash Flow | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Dividend per Share | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| **CAGR Over Five Years** | | | | | | | | | | | |
| Total Revenue | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| EBITDA | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| EBITA | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| EBIT | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Earnings from Cont. Ops. | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Net Income | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Normalized Net Income | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Diluted EPS before Extra | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Accounts Receivable | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Inventory | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Net PP&E | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Total Assets | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Tangible Book Value | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Common Equity | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Cash from Ops. | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Capital Expenditures | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Levered Free Cash Flow | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Unlevered Free Cash Flow | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Dividend per Share | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |

Bloomberg

# Company In Depth Fundamentals - Capital Structure Summary

| | | | | | |
|---|---|---|---|---|---|
| Ticker: | GEHC US EQUITY | Sort | Ascend | Currency | Reporting / Change / USD |
| Period Type | Quarters | Consolidated | Yes | Accounting | Mixed |

## GE HealthCare Technologies Inc

Sector: Salud  Industry: Equipo y servicios médicos  Sub-Industry: Equipo médico

| Y | -4FQ | -3FQ | -2FQ | -1FQ | -0FQ |
|---|---|---|---|---|---|
| **WACC** | | | | | |
| **For the Fiscal Period Ending** | **30/09/2022** | **31/12/2022** | **31/03/2023** | **30/06/2023** | **30/09/2023** |
| | **%** | **%** | **%** | **%** | **%** |
| **Equity** | | | | | |
| Cost of Equity | 9.4% | 16.0% | 8.9% | 9.9% | 10.5% |
| Weight of Equity | -- | 75.5% | 78.5% | 78.3% | 75.1% |
| **+ Debt** | | | | | |
| Cost of Debt | 4.2% | 4.2% | 3.8% | 4.2% | 4.7% |
| Weight of Debt | 100.0% | 24.5% | 21.5% | 21.7% | 24.9% |
| **+ Preferred Equity** | | | | | |
| Cost of Pref Equity | -- | -- | -- | -- | -- |
| Weight of Pref Equity | -- | 0.0% | 0.0% | 0.0% | 0.0% |
| **WACC** | **--** | **13.1%** | **7.8%** | **8.7%** | **9.0%** |

**Capital Structure**

| For the Fiscal Period Ending | 30/09/2022 | | 31/12/2022 | | 31/03/2023 | | 30/06/2023 | | 30/09/2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| *Currency* | *USD* | | *USD* | | *USD* | | *USD* | | *USD* | |
| | *Millions* | *% of Total* | *Millions* | *% of Total* | *Millions* | *% of Total* | *Millions* | *% of Total* | *Millions* | *% of Total* |
| Hist Market Cap | | | | | | | | | | |
| ST Borrowings | 12.0 | *27.9%* | 119.0 | *0.3%* | 5.0 | *0.0%* | 5.0 | *0.0%* | 7.0 | *0.0%* |
| LT Borrowings | 31.0 | *72.1%* | 8,477.0 | *24.1%* | 10,234.0 | *21.5%* | 10,233.0 | *21.7%* | 10,253.0 | *24.9%* |
| Pref Equity | -- | -- | 0.0 | *0.0%* | 0.0 | *0.0%* | 0.0 | *0.0%* | 0.0 | *0.0%* |
| **Total Capital** | **43.0** | ***100.0%*** | **35,142.0** | ***100.0%*** | **47,536.2** | ***100.0%*** | **47,189.1** | ***100.0%*** | **41,234.7** | ***100.0%*** |

**Debt Summary Data**

| For the Fiscal Period Ending | 30/09/2022 | | 31/12/2022 | | 31/03/2023 | | 30/06/2023 | | 30/09/2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| *Currency* | *USD* | | *USD* | | *USD* | | *USD* | | *USD* | |
| | *Millions* | *% of Total* | *Millions* | *% of Total* | *Millions* | *% of Total* | *Millions* | *% of Total* | *Millions* | *% of Total* |
| Total Commercial Paper | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Total Revolving Credit | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Total Capital Leases | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| General/Other Borrowings | | | | *100.0%* | 10,239.0 | *100.0%* | | *100.0%* | 10,260.0 | *100.0%* |
| **Total Principal Due** | **43.0** | ***100.0%*** | **8,596.0** | ***100.0%*** | **10,239.0** | ***100.0%*** | **10,238.0** | ***100.0%*** | **10,260.0** | ***100.0%*** |
| **Total Debt Outstanding** | **43.0** | | **8,596.0** | | **10,239.0** | | **10,238.0** | | **10,260.0** | |
| **Additional Totals** | | | | | | | | | | |
| Total Cash & ST Investments | 500.0 | *1162.8%* | 1,539.0 | *17.9%* | 2,327.0 | *22.7%* | 1,939.0 | *18.9%* | 2,418.0 | *23.6%* |
| Net Debt | -457.0 | *-1062.8%* | 7,057.0 | *82.1%* | 7,912.0 | *77.3%* | 8,299.0 | *81.1%* | 7,842.0 | *76.4%* |
| Total Short-Term Borrowings | 12.0 | *27.9%* | 119.0 | *1.4%* | 5.0 | *0.0%* | 5.0 | *0.0%* | 7.0 | *0.1%* |
| Curr. Port. of LT Debt/Cap. Leases | -- | -- | 104.0 | *1.2%* | -- | -- | -- | -- | -- | -- |
| Long-Term Debt (Incl. Cap. Leases) | 31.0 | *72.1%* | 8,477.0 | *98.6%* | 10,234.0 | *100.0%* | 10,233.0 | *100.0%* | 10,253.0 | *99.9%* |
| Total Secured Debt | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Fixed Rate Debt | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Variable Rate Debt | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| **Credit Ratios** | | | | | | | | | | |
| Net Debt/EBITDA | -- | | -- | | -- | | -- | | 2.5x | |
| Total Debt/EBITDA | -- | | -- | | -- | | -- | | 3.3x | |
| Operating Income/Total Debt | 14.1x | | 0.1x | | 0.1x | | 0.1x | | 0.1x | |
| LTM FCF/Total Debt | -- | | -- | | -- | | -- | | 0.2x | |
| LTM CFO/Total Debt | -- | | -- | | -- | | -- | | 0.2x | |
| EBIT/Interest Expense | 302.5x | | 13.2x | | 4.1x | | 4.2x | | 4.5x | |
| EBIT/Total Interest Expense | 302.5x | | 13.2x | | 4.1x | | 4.2x | | 4.5x | |
| Degree of Financial Leverage | 1.0x | | 1.1x | | 1.3x | | 1.3x | | 1.3x | |
| (EBITDA-CAPEX)/Interest Expense | -- | | 14.5x | | 4.2x | | 4.8x | | 5.0x | |
| EBITDA/Total Interest Expense | -- | | 15.8x | | 5.3x | | 5.3x | | 5.6x | |
| **Debt Schedule** | | | | | | | | | | |
| Debt Schedule In Yr 1 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Debt Schedule In Yr 2 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Debt Schedule In Yr 3 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Debt Schedule In Yr 4 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Debt Schedule In Yr 5 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Debt Schedule - Years 2 - 3 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Debt Schedule - Years 4 - 5 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Debt Schedule - Years 2 - 5 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Debt Schedule Beyond Yr 5 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| **Debt Schedule - Total Debt** | **--** | **--** | **--** | **--** | **--** | **--** | **--** | **--** | **--** | **--** |
| **Capital Lease Schedule** | | | | | | | | | | |
| Capital Leases - Year 1 | -- | -- | 83.0 | *33.5%* | -- | -- | -- | -- | -- | -- |
| Capital Leases - Year 2 | -- | -- | 63.0 | *25.4%* | -- | -- | -- | -- | -- | -- |
| Capital Leases - Year 3 | -- | -- | 44.0 | *17.7%* | -- | -- | -- | -- | -- | -- |
| Capital Leases - Year 4 | -- | -- | 29.0 | *11.7%* | -- | -- | -- | -- | -- | -- |
| Capital Leases - Year 5 | -- | -- | 16.0 | *6.5%* | -- | -- | -- | -- | -- | -- |
| Capital Leases - Years 2 - 3 | -- | -- | 107.0 | *43.1%* | -- | -- | -- | -- | -- | -- |
| Capital Leases - Years 4 - 5 | -- | -- | 45.0 | *18.1%* | -- | -- | -- | -- | -- | -- |
| Capital Leases - Years 2 - 5 | -- | -- | 152.0 | *61.3%* | -- | -- | -- | -- | -- | -- |
| Capital Leases Beyond Year 5 | -- | -- | 13.0 | *5.2%* | -- | -- | -- | -- | -- | -- |
| **Total Future Value of Capital Leases** | **--** | **--** | **248.0** | ***100.0%*** | **--** | **--** | **--** | **--** | **--** | **--** |
| Present Value of ST Capital Leases | -- | | -- | | -- | | -- | | -- | |
| Present Value of LT Capital Leases | -- | | -- | | -- | | -- | | -- | |
| **Operating Leases (Rental Expense) Schedule** | | | | | | | | | | |
| Rental Expense - Year 1 | -- | -- | 116.0 | *30.7%* | -- | -- | -- | -- | -- | -- |
| Rental Expense - Year 2 | -- | -- | 89.0 | *23.5%* | -- | -- | -- | -- | -- | -- |
| Rental Expense - Year 3 | -- | -- | 66.0 | *17.5%* | -- | -- | -- | -- | -- | -- |
| Rental Expense - Year 4 | -- | -- | 50.0 | *13.2%* | -- | -- | -- | -- | -- | -- |
| Rental Expense - Year 5 | -- | -- | 27.0 | *7.1%* | -- | -- | -- | -- | -- | -- |
| Rental Expense - Years 2 - 3 | -- | -- | 155.0 | *41.0%* | -- | -- | -- | -- | -- | -- |
| Rental Expense - Years 4 - 5 | -- | -- | 77.0 | *20.4%* | -- | -- | -- | -- | -- | -- |
| Rental Expense - Years 2 - 5 | -- | -- | 232.0 | *61.4%* | -- | -- | -- | -- | -- | -- |
| Rental Expense Beyond Year 5 | -- | -- | 30.0 | *7.9%* | -- | -- | -- | -- | -- | -- |
| Total Sublease Income | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| **Future Min Oper Lease Obligations** | **--** | **--** | **378.0** | ***100.0%*** | **--** | **--** | **--** | **--** | **--** | **--** |
| **Contractual Obligation Schedule** | | | | | | | | | | |
| Contractual Obligations - Year 1 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Contractual Obligations- Years 2-3 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Contractual Obligations- Years 4-5 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Contractual Obligations - Years 2 - 5 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Contractual Obligations - Beyond Year 5 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| **Total Contractual Obligations** | **--** | **--** | **--** | **--** | **--** | **--** | **--** | **--** | **--** | **--** |
| **Purchase Obligations** | **--** | | **--** | | **--** | | **--** | | **--** | |
| **Interest Rate Data** | | | | | | | | | | |
| W/Avg. Interest Rate - Long-term Debt | -- | | -- | | -- | | -- | | -- | |

Bloomberg

# Company In Depth Fundamentals - Segments

| | | | | | |
|---|---|---|---|---|---|
| Ticker: | GEHC US EQUITY | GEHC US EQUITY | Ascend | Currency | Reporting / Change / USD |
| Period Type | Annuals | Consolidated | Yes | Accounting | Mixed |

## GE HealthCare Technologies Inc

**Sector: Salud** **Industry: Equipo y servicios médicos** **Sub-Industry: Equipo médico**

| Y | -10FY | -9FY | -8FY | -7FY | -6FY | -5FY | -4FY | -3FY | -2FY | -1FY | -0FY |
|---|---|---|---|---|---|---|---|---|---|---|---|
| **REVENUE** | | | | | | | -- | 31/12/2019 | 31/12/2020 | 31/12/2021 | 31/12/2022 |
| **Revenue by Product** | | | | | | | | | | | |
| **For the Fiscal Period Ending** | -- | -- | -- | -- | -- | -- | -- | 31/12/2019 | 31/12/2020 | 31/12/2021 | 31/12/2022 |
| **Revenue** | | | | | | | | **16,633.00** | **17,164.00** | **17,585.00** | **18,341.00** |
| Imaging | 9,985.00 | 9,985.00 | 9,985.00 | 9,985.00 | 9,985.00 | 9,985.00 | 9,985.00 | 9,096.00 | 8,959.00 | 9,433.00 | 9,985.00 |
| Ultrasound | 3,422.00 | 3,422.00 | 3,422.00 | 3,422.00 | 3,422.00 | 3,422.00 | 3,422.00 | 2,783.00 | 3,675.00 | 3,172.00 | 3,422.00 |
| Patient Care Solutions (PCS) | 2,916.00 | 2,916.00 | 2,916.00 | 2,916.00 | 2,916.00 | 2,916.00 | 2,916.00 | 2,723.00 | 2,703.00 | 2,915.00 | 2,916.00 |
| Pharmaceutical Diagnostics (PDx) | 1,958.00 | 1,958.00 | 1,958.00 | 1,958.00 | 1,958.00 | 1,958.00 | 1,958.00 | 1,993.00 | 1,780.00 | 2,018.00 | 1,958.00 |
| Other | 60.00 | 60.00 | 60.00 | 60.00 | 60.00 | 60.00 | 60.00 | 38.00 | 47.00 | 47.00 | 60.00 |
| | - | - | - | - | - | - | - | - | - | - | - |
| | - | - | - | - | - | - | - | - | - | - | - |
| | - | - | - | - | - | - | - | - | - | - | - |
| | - | - | - | - | - | - | - | - | - | - | - |
| | - | - | - | - | - | - | - | - | - | - | - |

| **Revenue by Geography** | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| **For the Fiscal Period Ending** | -- | -- | -- | -- | -- | -- | -- | 31/12/2019 | 31/12/2020 | 31/12/2021 | 31/12/2022 |
| **Revenue** | | | | | | | | **16,633.00** | **17,164.00** | **17,585.00** | **18,341.00** |
| USCAN | 8,130.00 | 8,130.00 | 8,130.00 | 8,130.00 | 8,130.00 | 8,130.00 | 8,130.00 | 7,409.00 | 7,436.00 | 7,373.00 | 8,130.00 |
| EMEA | 4,684.00 | 4,684.00 | 4,684.00 | 4,684.00 | 4,684.00 | 4,684.00 | 4,684.00 | 4,061.00 | 4,663.00 | 4,535.00 | 4,684.00 |
| | 2,996.00 | 2,996.00 | 2,996.00 | 2,996.00 | 2,996.00 | 2,996.00 | 2,996.00 | 2,913.00 | 2,720.00 | 2,987.00 | 2,996.00 |
| | 2,531.00 | 2,531.00 | 2,531.00 | 2,531.00 | 2,531.00 | 2,531.00 | 2,531.00 | 2,250.00 | 2,345.00 | 2,690.00 | 2,531.00 |
| | - | - | - | - | - | - | - | - | - | - | - |
| | - | - | - | - | - | - | - | - | - | - | - |
| | - | - | - | - | - | - | - | - | - | - | - |
| | - | - | - | - | - | - | - | - | - | - | - |
| | - | - | - | - | - | - | - | - | - | - | - |
| | - | - | - | - | - | - | - | - | - | - | - |

**GROSS PROFIT BEF TAX**

**OPERATING PROFIT BEF TAX**

Bloomberg

# Company In Depth Fundamentals - Pension

| Ticker: | GEHC US EQUITY | Sort | Ascend | Currency | Reporting | Change | USD |
|---|---|---|---|---|---|---|---|
| Period Type | Annuals | Consolidated | Yes | Accounting | Mixed | | |

## GE HealthCare Technologies Inc

Sector: Salud  Industry: Equipo y servicios médicos  Sub-Industry: Equipo médico

| Y | -10FY | -9FY | -8FY | -7FY | -6FY | -5FY | -4FY | -3FY | -2FY | -1FY | -0FY |
|---|---|---|---|---|---|---|---|---|---|---|---|
| **Pension** | | | | | | | | | | | |
| **For the Fiscal Period Ending** | -- | -- | -- | -- | -- | -- | -- | 31/12/2019 | 31/12/2020 | 31/12/2021 | 31/12/2022 |
| *Currency* | *USD* | *USD* | *USD* | *USD* | *USD* | *USD* | *USD* | *USD* | *USD* | *USD* | *USD* |
| **Pension Net Periodic Cost** | | | | | | | | | | | |
| Service Cost | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Interest Cost | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Expected Return on Plan Assets | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Pension Expense (Income) | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| **Other Postretirement Cost** | | | | | | | | | | | |
| Service Cost | -- | -- | -- | -- | -- | -- | -- | 19.00 | 23.00 | 24.00 | 19.00 |
| Interest Cost | -- | -- | -- | -- | -- | -- | -- | 22.00 | 17.00 | 15.00 | 17.00 |
| Expected Return on Plan Assets | -- | -- | -- | -- | -- | -- | -- | (25.00) | (26.00) | (27.00) | (27.00) |
| Other Postretirement Benefits Expense (I | -- | -- | -- | -- | -- | -- | -- | 2.00 | (1.00) | - | - |
| **Pension Funded Status** | | | | | | | | | | | |
| Fair Value of Plan Assets | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Actual Return (Loss) on Plan Assets | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Employer Contribution | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Benefits Paid | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Projected Benefit Obligation | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Over(Under) Funded Pension | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Accumulated Benefit Obligation | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Pension Funding Ratio | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| **Other Postretirement Funded Status** | | | | | | | | | | | |
| Fair Value of Plan Assets | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Actual Return (Loss) on Plan Assets | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Employer Contribution | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Benefits Paid | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Projected Benefit Obligation | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Over(Under) Funded Post Ret Benefits | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Other Post-Retirement Funding Ratio | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| **Actuarial Assumptions** | | | | | | | | | | | |
| **Pension** | | | | | | | | | | | |
| Expected Return on Plan Assets | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Discount Rate used on Plan Liabilities | -- | -- | -- | -- | -- | -- | -- | 1.80 | 1.44 | 1.91 | 4.26 |
| Rate of Compensation Increase | -- | -- | -- | -- | -- | -- | -- | 2.85 | 2.65 | 2.81 | 2.99 |
| **Other Postretirement Benefits** | | | | | | | | | | | |
| Expected Return on Plan Assets | -- | -- | -- | -- | -- | -- | -- | 5.82 | 5.40 | 5.39 | 6.32 |
| Discount Rate used on Plan Liabilities | -- | -- | -- | -- | -- | -- | -- | 2.50 | 1.80 | 1.44 | 1.91 |
| Health Care Cost Trend Projected(next y | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| **Pension Plan Asset Allocation** | | | | | | | | | | | |
| Fair Value of Plan Assets | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Asset Category - Equities % | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Asset Category - Debt % | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Asset Category - Real Estate % | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Asset Category - Company Stock % | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Asset Category - Cash % | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Asset Category - Other % | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| **Expected Pension Payments** | | | | | | | | | | | |
| Year 1 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Year 2 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Year 3 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Year 4 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Year 5 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Beyond Year 5 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| **Expected Postretirement Benefits** | | | | | | | | | | | |
| Year 1 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Year 2 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Year 3 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Year 4 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Year 5 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Beyond Year 5 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |

Bloomberg

# Company In Depth Fundamentals - Supplemental

| Ticker: | GEHC US EQUITY | Sort | Ascend | Currency | Reporting / Change | USD |
|---|---|---|---|---|---|---|
| Period Type | Annuals | Consolidated | Yes | Accounting | Mixed | |

## GE HealthCare Technologies Inc

**Sector: Salud** **Industry: Equipo y servicios médicos** **Sub-Industry: Equipo médico**

| Y | -10FY | -9FY | -8FY | -7FY | -6FY | -5FY | -4FY | -3FY | -2FY | -1FY | -0FY |
|---|---|---|---|---|---|---|---|---|---|---|---|
| **Supplemental** | | | | | | | | | | | |
| **For the Fiscal Period Ending** | -- | -- | -- | -- | -- | -- | -- | 31/12/2019 | 31/12/2020 | 31/12/2021 | 31/12/2022 |
| ***Currency*** | *USD* | *USD* | *USD* | *USD* | *USD* | *USD* | *USD* | *USD* | *USD* | *USD* | *USD* |
| **Options Activity** | | | | | | | | | | | |
| Options Granted During Period | - | - | - | - | - | - | - | - | - | - | - |
| Options Outstanding End Of Period | - | - | - | - | - | - | - | - | - | - | - |
| Options Exercisable End of Period | - | - | - | - | - | - | - | - | - | - | - |
| **Price** | | | | | | | | | | | |
| Weighted Average Fair Value per Option | - | - | - | - | - | - | - | - | - | - | - |
| Avg Exercise Price (Options Outstanding) | - | - | - | - | - | - | - | - | - | - | - |
| Avg Exercise Price (Options Exercisable) | - | - | - | - | - | - | - | - | - | - | - |
| Stock Option Valuation Model | - | - | - | - | - | - | - | - | - | - | - |
| **Assumptions** | | | | | | | | | | | |
| Stock Opt Valuation - Risk Free Rate (%) | - | - | - | - | - | - | - | - | - | - | - |
| Stock Opt Valuation - Expected Life (Yrs) | - | - | - | - | - | - | - | - | - | - | - |
| Stock Opt Valuation - Expected Volatil (%) | - | - | - | - | - | - | - | - | - | - | - |
| Stock Opt Valuation - Dividend Yield (%) | - | - | - | - | - | - | - | - | - | - | - |
| **Stock Expense** | | | | | | | | | | | |
| Expense For Stock-Based Compensation | - | - | - | - | - | - | - | - | - | - | - |
| Stock Option Expense (After Tax) | - | - | - | - | - | - | - | - | - | - | - |